How I Treat ALL: Do All Adults with Ph+ ALL Still Require Allogeneic Transplant?

Description

Survival rates for patients with Ph+ ALL have improved significantly in the last decade with the introduction of abl-kinase (TKI) inhibitors to frontline therapy. A variety of regimens incorporating TKI and chemotherapy combinations have emerged and have resulted in high molecular remission rates. Given these high molecular remission rates, there is emerging controversy about the requirement of hematopoietic cell transplantation for long-term survival. Dr. Stock will evaluate both transplant and non-transplant approaches that have been studied in prospective clinical trials and discuss new approaches for targeted treatment for Ph+ ALL.

Presenters

  • Wendy Stock

Pricing

Member Type Price
List Price $30.00
Active, International, Emeritus, and Honorary Members $20.00
Associate, International Associate, Student, and Resident Members $20.00
back to top